|
|
7/29/2003 8:13 AM ET
SWISS MEDICA APPOINTS RONALD F. SPRINGER TO BOARD OF DIRECTORS
Stock Symbol: OTC BB: SWME
July 29, 2003
SWISS MEDICA APPOINTS RONALD F. SPRINGER TO BOARD OF DIRECTORS
Toronto, Canada / Munich, Germany – Raghu Kilambi, Chairman and CEO of Swiss Medica, is pleased to
announce that Ronald Springer has been appointed to the board of directors.
Mr. Springer is a seasoned operational executive with 20 years of experience in the natural health, financial
services and environmental fields. Mr. Springer is currently President and CEO of General Cosmetics
Corporation, a private U.S. natural health product development company with offices in Germany and Brazil.
Swiss Medica acquired the O24 Sport Pain Relief product line, including all Patents and Trademarks, from
General Cosmetics in May 2003 in exchange for common shares of Swiss Medica.
Mr. Springer earned a business degree in Germany and is a citizen of both Germany and the United States. In
1979, Mr. Springer founded the first OTC brokerage firm in Hamburg, Germany. He has operated business
ventures in Europe, South America and the United States, and was the Founder of several environmental
companies. In 1987, Mr. Springer founded Global Capital Securities, a full-service New York-based investment
bank with 400 employees that was focused on the underwriting of equity securities. Since 1993, Mr. Springer’s
main focus has been on preventive medicine and the research and development of herbal medicines and
alternative health systems and products.
Mr. Springer’s grandfather and mentor was an innovator in natural and herbal medicine in Europe in the 1920’s
and lived to be almost 90 years old without ever seeing a medical doctor, proving that “a healthy body is the best
doctor”. Mr. Springer strived to further his grandfather’s vision and in 1993, founded Heaven from Earth Inc.
which formed the nucleus of General Cosmetics Corporation that developed the unique O24 patented, 100%
pure, all natural pain relief product family. Mr. Springer’s family, friends and partners spent 10 years and millions
of dollars building the O24 brand in Europe as a pain relief solution for elite athletes and patients in hospitals.
General Cosmetics sold the O24 Sport Line to Swiss Medica, and became the major Swiss Medica shareholder
to leverage Swiss Medica’s strong North American mainstream consumer distribution relationships.
"General Cosmetics is very excited to partner with Swiss Medica. The O24 product received very strong
testimonials from the European sports and medical communities and delivered strong results in several clinical
studies in the European hospital environment. Swiss Medica is now starting to get similar very positive
testimonials in North America. We are pleased to be working with Swiss Medica's experienced team to offer this
life enhancing product to the mainstream consumer who suffers from real pain”, stated Mr. Springer.
"I am very pleased that Ronald accepted our invitation to join the Swiss Medica board. Swiss Medica is currently
preparing a mainstream North American commercial launch of the revolutionary, patented, all natural O24 pain
relief product family through several distribution channels. The advice and support of Ronald and the other
General Cosmetics' executives has streamlined this process and allowed us to leverage their experience and
distribution networks", commented Raghu Kilambi.
About Swiss Medica Inc.
Swiss Medica Inc. is focused on acquiring over-the-counter bioscience products with demonstrated competitive
advantages and increasing their revenues by focused sales and marketing efforts in selected distribution
channels including retail, direct sales, direct response, and e-commerce. Swiss Medica’s mission is to be a world
leader in the acquisition and commercialization of life enhancing bioscience products that improve quality of
lives. Please visit our website at www.swissmedica.com
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica’s services, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
Investor Relations Contact:
Dave Jones: 705 495 0022
djones@swissmedica.com
|
|
